Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc at Piper Sandler Healthcare Conference (Virtual)- Pre-recorded Fireside Chat Transcript

Nov 20, 2020 / 08:26PM GMT
Release Date Price: $36.45 (-0.38%)
Joseph Michael Catanzaro
Piper Sandler & Co., Research Division - VP & Senior Biotech Analyst

Perfect. Well, thanks so much to everybody who's tuning in here. I'm Joe Catanzaro. I'm one of Piper's biotech analyst.

It's my pleasure to welcome Iovance and their President and CEO, Maria Fardis. Maria, thanks so much for making the time here.

Questions & Answers

Joseph Michael Catanzaro
Piper Sandler & Co., Research Division - VP & Senior Biotech Analyst

I guess if we could just jump straight into it and, obviously, maybe start with non-small cell lung cancer. So we recently got some details around the Phase II IOV-LUN-202 trial design. I guess, first, walk us through that trial design and, specifically, the thought process that went into the type of patients that you want to enroll into those cohorts given sort of the emphasis you had put into the thought process around designing this trial.

Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director

Yes, absolutely

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot